Introduction {#s1}
============

Cytogenetic analysis has been used in the etiological diagnosis for pediatric patients with developmental delay (DD), intellectual disability (ID), multiple congenital anomalies (MCA), and autistic spectrum disorders (ASD) and for pregnancies in risk of chromosomal abnormalities or with fetal defects ([@B32]; [@B38]). Chromosomal analysis has been effective in detecting numerical and structural chromosomal abnormalities on cultured cells from specimens obtained from peripheral blood (PB), amniocentesis (AC), and chorionic villus sampling (CVS) despite its analytical resolution limited by the average G-band size of 5--10 megabase (Mb). Fluorescence *in situ* hybridization (FISH) in metaphase or interphase cells using labeled DNA probes of 100--800 kilobase (Kb) has improved the analytical resolution allowing detection of the targeted microdeletions, microduplications, and rearrangements. Multiple FISH panels with targeted probes have been used to detect common aneuploidies and cryptic subtelomeric rearrangements ([@B29]; [@B24]). Conventional cytogenetic evaluation of ID/DD/MCA showed an abnormality detection rate (ADR) of 3.7% for numerical and large structural chromosomal abnormalities and up to 6.8% when combined with FISH analysis for targeted cryptic and subtelomeric rearrangements ([@B30]).

In the past decade, genome-wide microarray analysis using array comparative genomic hybridization (aCGH) or single nucleotide polymorphism (SNP) chip has been validated and applied as the first-tier genetic testing for pediatric patients with ID/DD/MCA ([@B45]; [@B23]). The application of aCGH for large case series of newborns and pediatric patients has been reported. The ADR of cytogenomic abnormalities from pediatric patients with ID/DD/MCA and autism is in the range of 12%--20% ([@B46]; [@B2]; [@B28]). Significantly improved diagnostic yield of pathogenic copy number variants (pCNVs) from pediatric patients has led to a rapid application of this genomic analysis for prenatal diagnosis ([@B43]; [@B51]). Opinion and guidelines for prenatal diagnosis using microarray analysis have been introduced by the American College of Obstetricians and Gynecologists and the American College of Medical Genetics and Genomics ([@B1]; [@B33]). Integration of microarray analysis into conventional cytogenetic analysis has been effective in defining the gene contents and genomic coordinates for recurrent genomic disorders and chromosomal structural imbalances.

This report, a retrospective analysis of prenatal and pediatric cases over a 10-year interval in the Yale Clinical Cytogenetics Laboratory, has revealed the difference in diagnostic yield on the spectrum of cytogenomic abnormalities. The findings from this study provide guidance for future improvement of prenatal and pediatric diagnosis of cytogenomic abnormalities.

Materials and Methods {#s2}
=====================

Subjects {#s2_1}
--------

The Yale Laboratory of Clinical Cytogenetics is CLIA-certified and provides diagnostic services for prenatal and pediatric patients. Clinical cases referred for cytogenetic analysis and test results during the interval of 2008--2017 were retrieved from the laboratory's CytoAccess database ([@B44]), which showed 3,608 consecutive prenatal cases and 4,509 consecutive pediatric cases (age \<18 years old) for a total of 8,117 cases. Standardized karyotyping, FISH, and aCGH tests were performed for the prenatal and pediatric patients following requisitions of referring physicians. Of the 3,608 prenatal cases, 2,269 cases were analyzed by karyotyping only, 781 cases were by karyotyping and aCGH, 331 cases were by karyotyping and FISH, 185 cases were by karyotyping, aCGH, and FISH, 31 cases were by aCGH only, seven cases by aCGH and FISH, and four cases were by FISH only. Of the 4,509 pediatric cases, 1,526 cases were analyzed by aCGH only, 1,401 cases by karyotyping and aCGH, 1,091 by karyotyping only, 194 cases by karyotyping, FISH, and aCGH, 133 cases by karyotyping and FISH, 89 cases by aCGH and FISH, and 75 cases by FISH only. For this retrospective study, there were no pre-study requirements on the patient's clinical indications and specimens and there was no post-study interaction with the patients and their families. This project was determined as a chart review retrospective study and deemed exempted from Institutional Review Board (IRB) approval and granted waiver of consent based on the policy of the Yale University IRB.

Karyotyping, FISH, and aCGH {#s2_2}
---------------------------

Karyotyping was performed on G-band metaphases prepared from cultured cells of PB, AC, and CVS following the laboratory's standardized procedures. FISH tests using the AneuVysion probes (Abbott Inc. Des Plaines, IL) were performed for rapid detection of common aneuploidies involving chromosomes X, Y, 13, 18, and 21. FISH tests using probes for known microdeletion and microduplication loci (Cytocell Inc. Cambridge, UK) were performed for a rapid screening or confirmation.

Oligonucleotide aCGH analysis was performed on genomic DNA extracted from peripheral blood lymphocytes, directly prepared villi cells or cultured amniocytes using the Gentra Puregene Kit (Qiagen, Valencia, CA). The DNA concentration was measured using a Nano-Drop spectrophotometer (Thermo Fisher Scientific, Inc. Waltham, MA). High molecular weight DNA was verified by agarose gel electrophoresis. For each sample, 2 ug of genomic DNA was used following the manufacturer's protocol from the Agilent Human Genome CGH microarray 180K kit (110,712 CGH + 59,647 SNP 60-mer oligonucleotides) and 400K kit (292,097 CGH + 119,091 SNP 60-mer oligonucleotide probes) (Agilent Technologies, Inc., Santa Clara, CA). This aCGH procedure can achieve 99% sensitivity and 99% specificity using a sliding window of five to seven contiguous oligonucleotides, indicating an analytical resolution of 100--150 Kb for the 180K kit and 40--60 Kb for the 400K kit ([@B45]). The genomic coordinates for detected aberrations from this aCGH analysis were based on the February 2009 Assembly (GRCh37/hg19) of the UCSC Human Genome browser (<http://genome.ucsc.edu/>).

Categorization of the Cytogenomic Abnormalities {#s2_3}
-----------------------------------------------

The spectrum of cytogenomic abnormalities was divided into two major categories: chromosomal abnormalities and submicroscopic genomic aberrations which were pCNVs that are 5--10 Mb and less. The chromosomal abnormalities were further divided into two major types: (1) numerical abnormalities including sex chromosome aneuploidies (47,XXY, 47,XYY, other X or Y aneuploidies for males and 45,X, 47,XXX, other X aneuploidies for females), autosomal aneuploidies (trisomy 21, trisomy 18, trisomy 13, and other autosomal aneuploidies), and polyploidies (triploidy and tetraploidy); and (2) structural abnormalities including balanced rearrangements (reciprocal translocations, Robertsonian translocations, inversions, etc.) and unbalanced structural rearrangements (deletions, duplications, marker chromosomes, etc.) ([@B25]). Based on the American College of Medical Genetics and Genomics (ACMG) standards and guidelines, only pCNVs were included in this study ([@B15]). The detected pCNVs were further divided into two major types: (1) recurrent genomic disorders (also termed as microdeletion and microduplication syndromes) induced by low copy repeats and segmental duplications, and (2) sporadic pCNVs detected in the subtelomeric and interstitial regions. Excluding the recurrent genomic disorders, pCNVs detected at the terminal 10--15 Mb in large autosomes numbered 1 to 12 and terminal 5--10 Mb in small autosomes numbered 13 to 22, were usually considered to be subtelomeric pCNVs; pCNVs found between centromeric and subtelomeric regions were interstitial pCNVs ([@B47]). The workflow of prenatal and pediatric case processing with detected cytogenomic abnormalities and their categories is depicted in [**Figure 1**](#f1){ref-type="fig"}.

![Flow-diagram for detection and categorization of cytogenomic abnormalities in prenatal and pediatric cases. aCGH, array comparative genomic hybridization; Chr, chromosome; FISH, fluorescence *in situ* hybridization; pCNVs, pathogenic copy number variants.](fgene-10-01162-g001){#f1}

Comparison of ADR and RF From Prenatal and Pediatric Cases {#s2_4}
----------------------------------------------------------

To evaluate the diagnostic accuracy for various types of abnormalities in prenatal or pediatric settings, ADR in prenatal and pediatric patients was calculated by the number of abnormal cases divided by the total number of patients. Among the prenatal cases, the ADR of chromosomal abnormalities was calculated by the number of abnormal chromosomal cases divided by the total number of 3,608 prenatal cases; the ADR of pCNVs was calculated by the number of pCNVs cases divided by the number of 1,004 prenatal cases analyzed by aCGH. Among pediatric patients, the ADR of chromosomal abnormalities was calculated by the number of abnormal chromosomal cases divided by the total number of 4,443 cases, which included 4,434 cases analyzed by karyotyping or aCGH and nine FISH only cases for common aneuploidies; the ADR of pCNVs was calculated by the number of pCNVs cases divided by the total number of 3,276 cases, which included 3,210 cases analyzed by aCGH and 66 FISH only cases for specific microdeletions or microduplications. The ADR for chromosomal abnormalities and pCNVs was based on the different number of cases performed and was considered as a composite ADR.

To evaluate the spectrum of chromosomal abnormalities and pCNVs in prenatal or pediatric settings, relative frequency (RF) was determined by the number of abnormal prenatal or pediatric cases in each major type divided by the total number of chromosomal abnormalities or pCNVs in prenatal or pediatric cases, respectively. Chi-square tests were applied to compare ADR of chromosomal abnormalities and pCNVs between prenatal and pediatric cases and a P value of less than 0.05 was considered statistically significant.

Estimating Prevalence and Diagnostic Efficacy of Cytogenomic Abnormalities {#s2_5}
--------------------------------------------------------------------------

Constitutional chromosomal aneuploidies are the result of nondisjunction in meiosis in the great majority. Recurrent genomic disorders are caused by nonallelic homologous recombination (NAHR) mediated by low copy repeats or segmental duplications. Even though genomic disorders are caused by the same mechanism, prevalence of specific disorders varied from relatively common to extremely rare due to the genomic structure of low copy repeats or segmental duplications ([@B10]). A linear regression analysis was performed to correlate the ADR in the pediatric setting with epidemiological data for DiGeorge/velocardiofacial syndrome (DGS/VCFS, 22q11.21 deletion), Williams-Beuren syndrome (WBS, 7q11.23 deletion), Prader-Willi/Angelman syndromes (PWS/AS, 15q11-q13 deletion), Smith-Magenis syndrome (SMS, 17p11.2 deletion), and hereditary neuropathy with liability to pressure palsies (HNPP, 17p12 deletion) ([@B11]; [@B16]; [@B22]; [@B37]; [@B27]; [@B31]; [@B10]). Correlation with a P value less than 0.05 was considered statistically significant and was further used to extrapolate the prevalence of other rare genomic disorders, including recurrent genomic disorders and pCNVs. By a similar procedure, a linear correlation between the ADR of 45,X (Turner syndrome, TS), trisomy 21 (Down syndrome, DS), trisomy 18, and trisomy 13 in the pediatric setting and their incidences ([@B25]) was used to estimate the diagnostic outcome of 47,XXY, 47,XYY, 47,XXX, and balanced Robertsonian translocations.

Given the known incidence of DS and DGS, the ratio of DS/DGS was used as a simple measurement of efficacy in detecting chromosome abnormalities and pCNVs. From the average annual abnormal cases of DS and DGS, the size of the population served was estimated. The expected number of abnormal cases with chromosomal abnormalities and pCNVs was calculated from known incidence or prevalence times the estimated population served. Diagnostic efficacy, defined as the likelihood of a patient with a cytogenomic abnormality being detected in current prenatal or pediatric clinical setting, was calculated by detected number of abnormal cases divided by expected number of abnormal cases.

Results {#s3}
=======

Prenatal and Pediatric Caseloads {#s3_1}
--------------------------------

The prenatal and pediatric caseloads during 2008--2017 were shown in [**Figure 2**](#f2){ref-type="fig"}. The annual prenatal caseload showed a decrease from 595 cases in 2008 to 219 cases in 2013, and then stabilized at around 210 cases annually from 2013 to 2017. Although aCGH had been increasingly applied to prenatal diagnosis, karyotyping was still requested in almost all prenatal cases. In the 10-year period, less than one third of total prenatal cases had aCGH. The annual pediatric caseload was relatively stable, and the most frequently applied analytical method to pediatric cases has changed from karyotyping to aCGH.

![The prenatal and pediatric caseloads during 2008--2017. **(A)** The total number of cases and **(B)** the annual number of cases analyzed by karyotyping, aCGH, and FISH in the prenatal setting. **(C)** The total number of cases and **(D)** the annual number of cases analyzed by karyotyping, aCGH and FISH in the pediatric setting. aCGH, array comparative genomic hybridization; FISH, fluorescence *in situ* hybridization.](fgene-10-01162-g002){#f2}

Diagnostic Yields of Cytogenomic Abnormalities in Prenatal and Pediatric Settings {#s3_2}
---------------------------------------------------------------------------------

Cytogenomic abnormalities were detected in a total of 560 prenatal cases and 674 pediatric cases, and the ADR in prenatal and pediatric settings were 15.52% (560/3,608) and 14.95% (674/4,509), respectively. Details of all abnormal prenatal and pediatric cases are summarized in the supplemental files ([**Tables S1**](#SM1){ref-type="supplementary-material"}--[**S4**](#SM4){ref-type="supplementary-material"}). The ADR of chromosomal abnormalities in prenatal cases was 14.80% which was significantly higher than the ADR of 7.97% in pediatric cases (p \< 0.05). The ADR of pCNVs in prenatal cases was 2.59% which was significantly lower than the ADR of 9.77% in pediatric cases (p \< 0.05).

The major types of chromosomal abnormalities in prenatal and pediatric cases are summarized in [**Table 1**](#T1){ref-type="table"} and [**S5**](#SM5){ref-type="supplementary-material"}. The ADR for sex chromosome aneuploidies, autosomal aneuploidies, balanced structural rearrangements, and unbalanced rearrangements were 1.77%, 10.53%, 0.91%, and 0.86% for prenatal cases, and 1.42%, 3.71%, 0.63%, and 2.21% for pediatric cases. In prenatal cases, the most frequently seen numerical chromosomal abnormalities by RF were trisomy 21, trisomy 18, 45,X, and trisomy 13 at 42.51%, 15.36%, 8.8%, and 4.12%, respectively, which accounted for 70.79% of the chromosome abnormalities. In pediatric cases, the most frequently seen numerical chromosomal abnormalities by RF were trisomy 21, 47,XXY, 45,X, and trisomy 18 at 42.37%, 7.63%, 6.78%, and 2.82%, respectively, which accounted for 59.6% of the chromosome abnormalities. [**Figures 3A, B**](#f3){ref-type="fig"} show the number of cases of common aneuploidies detected in prenatal and pediatric cases. For structural chromosomal abnormalities, RF for balanced and unbalanced rearrangements were 6.18% and 5.81% for prenatal cases and 7.91% and 27.68% for pediatric cases, respectively.

###### 

Chromosomal abnormalities detected in prenatal and pediatric settings.

  Chromosomal abnormalities           Prenatal   Pediatric                                       
  ----------------------------------- ---------- ----------- ------------ --------- ------------ ------------
  **Numerical abnormality**                                                                      
  **Sex Chromosome Aneuploidy**                                                                  
  Males                                                                                          
  47,XXY                              8          0.22        1.50         27        0.61\*       7.63
  47,XYY                              2          0.06        0.37         5         0.11         1.41
  Females                                                                                        
  45,X                                47         1.30        8.80         24        0.54\*       6.78
  47,XXX                              7          0.19        1.31         7         0.16         1.98
  **Subtotal**                        **64**     **1.77**    **11.99**    **63**    **1.42**     **17.80**
  **Autosomal Aneuploidy**                                                                       
  Trisomy 21                          227        6.29        42.51        150       3.38\*       42.37
  Trisomy 18                          82         2.27        15.36        10        0.23\*       2.82
  Trisomy 13                          22         0.61        4.12         3         0.07\*       0.85
  Other aneuploidy                    49         1.36        9.18         2         0.05\*       0.56
  **Subtotal**                        **380**    **10.53**   **71.16**    **165**   **3.71\***   **46.61**
  **Triploid &tetraploid**            **26**     **0.72**    **4.87**     **0**                  
  **Total**                           **470**    **13.03**   **88.01**    **228**   **5.13\***   **64.41**
  **Structural abnormality**                                                                     
  **Balanced rearrangements**                                                                    
  Robertsonian translocations         6          0.17        1.12         4         0.09         1.13
  Other                               27         0.75        5.06         24        0.54         6.78
  **Subtotal**                        **33**     **0.91**    **6.18**     **28**    **0.63**     **7.91**
  **Unbalanced rearrangements**       **31**     **0.86**    **5.81**     **98**    **2.21\***   **27.68**
  **Total**                           **64**     **1.77**    **11.99**    **126**   **2.84\***   **35.59**
  **All chromosomal abnormalities**   **534**    **14.80**   **100.00**   **354**   **7.97\***   **100.00**

ADR (abnormality detection rate by %): no. abn cases/3608 prenatal cases; no. abn cases/4443 pediatric cases. (4443 pediatric cases including 4434 cases analyzed by karyotyping or aCGH and 9 cases by FISH only for common aneuploidies). RF (relative frequency by %): no. abn cases/534 total prenatal chr abn; no. abn cases/354 total pediatric chr abn. \*Statistically different from ADR in prenatal setting (p \< 0.05).

![The number of cases with common chromosomal abnormalities detected in **(A)** prenatal and **(B)** pediatric settings. The number of cases with common recurrent genomic disorders detected in **(C)** prenatal and **(D)** pediatric settings.](fgene-10-01162-g003){#f3}

The types of pCNVs detected in prenatal and pediatric cases are summarized in [**Table 2**](#T2){ref-type="table"}. The ADR for recurrent genomic disorders and sporadic pCNVs were 1.69% and 0.90% for prenatal cases, and 7.08% and 2.69% for pediatric cases, respectively. These results showed significant under detection of pCNVs in prenatal cases (P \<0.05). [**Figures 3C, D**](#f3){ref-type="fig"} show the number of cases of 10 recurrent genomic disorders most commonly detected in prenatal and pediatric cases. Only a few genomic disorders at 22q11.21, 16p13.11, 17p13.3, and 15q13 loci were detected prenatally. The most frequently seen recurrent genomic disorders by RF were microdeletions and duplications at 22q11.21, 15q11-q13, 16p11.2, Xp22.31, 1q21, 7q11.23, 16p13.11, 17q12, 3q29, and 17p12 at 17.81%, 11.56%, 6.88%, 5.31%, 4.69%, 4.38%, 3.13%, 2.81%, 2.19%, and 2.19% in pediatric cases, respectively.

###### 

pCNVs detected in prenatal and pediatric settings.

  Type of pCNVs            Prenatal   Pediatric                                         
  ------------------------ ---------- ----------- ------------- --------- ------------- ------------
  **Genomic Disorders**                                                                 
  **22q11.21**             **7**      **0.70**    **26.92**     **57**    **1.74\***    **17.82**
  Del/Dup                  4/3        0.40/0.30   15.38/11.54   46/11     1.40/0.34\*   14.38/3.44
  **15q11-15q13**          **1**      **0.10**    **3.85**      **37**    **1.13\***    **11.57**
  Del/Dup                  -/1        -/0.10      -/3.85        31/6      0.95/0.18     9.69/1.88
  **16p11.2**                                                   **22**    **0.67**      **6.88**
  Del/Dup                                                       15/7      0.46/0.21     4.69/2.19
  **Xp22.31**                                                   **17**    **0.52**      **5.32**
  Del/Dup                                                       7/10      0.21/0.31     2.19/3.13
  **1q21**                                                      **15**    **0.46**      **4.70**
  Del/Dup                                                       3/10      0.09/0.31     0.94/3.13
  Del & Dup                                                     2         0.06          0.63
  **7q11.23**                                                   **14**    **0.42**      **4.38**
  Del/Dup                                                       8/6       0.24/0.18     2.50/1.88
  **16p13.11**             **3**      **0.30**    **11.54**     **10**    **0.30**      **3.13**
  Del/Dup                  3/-        0.30/-      11.54/-       4/6       0.12/0.18     1.25/1.88
  **17q12**                                                     **9**     **0.27**      **2.81**
  Del/Dup                                                       5/4       0.15/0.12     1.56/1.25
  **3q29**                                                      **7**     **0.21**      **2.19**
  Del/Dup                                                       6/1       0.18/0.03     1.88/0.31
  **17p12**                **1**      **0.10**    **3.85**      **7**     **0.21**      **2.19**
  Del/Dup                  1/-        0.10/-      3.85/-        2/5       0.06/0.15     0.63/1.56
  **17p13.3**              **2**      **0.20**    **7.69**      **6**     **0.18**      **1.88**
  Del/Dup                  1/1        0.10/0.10   3.85/3.85     4/2       0.12/0.06     1.25/0.63
  **8p23.1**                                                    **5**     **0.15**      **1.56**
  Del/Dup                                                       4/1       0.12/0.03     1.25/0.31
  **5q35 deletion**                                             **5**     **0.15**      **1.56**
  **15q13**                **2**      **0.20**    **7.69**      **4**     **0.12**      **1.25**
  Del/Dup                  1/1        0.10/0.10   3.85/3.85     1/3       0.03/0.09     0.31/0.94
  **2q13**                                                      **3**     **0.09**      **0.93**
  Del/Dup                                                       1/1       0.03/0.03     0.31/0.31
  Del & Dup                                                     1         0.03          0.31
  **17p11.2**                                                   **3**     **0.09**      **0.94**
  Del/Dup                                                       2/1       0.06/0.03     0.63/0.31
  **7q35-7q36 deletion**                                        **3**     **0.09**      **0.94**
  **17q21.31**                                                  **2**     **0.06**      **0.62**
  Del/Dup                                                       1/1       0.03/0.03     0.31/0.31
  **17q11.2 deletion**                                          **2**     **0.06**      **0.62**
  **22q13.33 deletion**                                         **2**     **0.06**      **0.62**
  **4q35 deletion**                                             **1**     **0.03**      **0.31**
  **Xq28 duplication**     **1**      **0.10**    **3.85**      **1**     **0.03**      **0.31**
  **Total**                **17**     **1.69**    **65.38**     **232**   **7.08\***    **72.50**
  **Sporadic pCNVs**                                                                    
  Subtelomeric pCNVs       5          0.50        19.23         35        1.07          10.94
  Interstitial pCNVs       4          0.40        15.38         53        1.62\*        16.56
  **Total**                **9**      **0.90**    **36.42**     **88**    **2.69\***    **27.50**
  **All pCNVs**            **26**     **2.59**    **100.00**    **320**   **9.77\***    **100.00**

pCNVs, pathogenic copy number variants; Del/Dup, deletion/duplication; ADR (abnormality detection rate by %): no. abn cases/1004 prenatal cases, no. abn cases/3276 pediatric cases (3276 pediatric cases including 3210 cases analyzed by aCGH and 66 cases by FISH only for specific microdeletions or microduplications). RF (relative frequency by%): no. abn cases/26 prenatal abn cases; no. abn case/320 pediatric abn cases. \*Statistically different from ADR in prenatal setting (p \< 0.05).

The composite ADR and RF for the spectrum of chromosomal abnormalities and pCNVs in prenatal and pediatric cases are shown in [**Figure 4**](#f4){ref-type="fig"}. A comparison between the spectrum of chromosomal abnormalities and pCNVs showed a significant under detection of unbalanced rearrangements and pCNVs in current prenatal setting (p \< 0.05).

![The ADR and RF of cytogenomic abnormalities detected in prenatal and pediatric settings. **(A)** The composite ADR of cytogenomic abnormalities in prenatal and pediatric settings. **(B/C)** The RF for the spectrum of chromosomal abnormalities and the spectrum of pCNVs in prenatal and pediatric settings. The red dot line separates the abnormalities into two groups per classification. ADR, abnormality detection rate; b-Rob, balanced Robertsonian translocations; chr abn, chromosomal abnormality; del/dup, deletion/duplication; inter-pCNV, interstitial pCNV; OA, other aneuploidy; OBR, other balanced rearrangements; pCNVs, pathogenic copy number variants; RF, relative frequency; subtel-pCNV, subtelomeric pCNV; T21, trisomy 21; T18, trisomy 18; T13, trisomy 13; Tri/tetra, triploid and tetraploid; UR, unbalanced rearrangements.](fgene-10-01162-g004){#f4}

Correlating ADR With Disease Prevalence for Cytogenomic Abnormalities {#s3_3}
---------------------------------------------------------------------

Correlating ADR from current diagnostic practice with known prevalence of common genomic disorders was used to extrapolate the prevalence of rare genomic disorders ([@B10]). The correlation between the reported prevalence of selected genomic disorders with their ADR at Yale Clinical Cytogenetics Laboratory was determined (Y = 0.0348X + 0.0039; R² = 0.8758, p = 0.019) ([**Figure 5A**](#f5){ref-type="fig"} and [**Table 3**](#T3){ref-type="table"}). Using this linear regression correlation, the prevalence of other syndromic genomic disorders was estimated as the following: 0.009% (1/10965) for 1q21.1 deletion syndrome, 0.017% (1/5960) for 1q21.1 duplication syndrome, 0.010% (1/9839) for 3q29 deletion syndrome, 0.020% (1/5025) for 16p11.2 deletion syndrome, and 0.009% (1/10965) for 17q12 deletion syndrome. The prevalence of detected recurrent genomic disorders and the total pCNVs was estimated to be 0.250% (1/396) and 0.344% (1/291), respectively. The estimated prevalence of these genomic disorders was in range with that from another report ([@B10]). This result also indicated that the aCGH was effective in detecting common genomic disorders in current pediatric setting.

![Correlation of prevalence with abnormal detection rate in pediatric setting by linear regression analysis. **(A)** Abnormality detection rate in pediatric setting was plotted against the reported prevalence for DGS/VCFS (velocardiofacial syndrome), WBS (Williams-Beuren syndrome), PWS/AS (Prader-Willi/Angelman syndromes), SMS (Smith-Magenis syndrome), and HNPP (hereditary neuropathy with liability to pressure palsies). **(B)** Abnormality detection rate in pediatric setting was plotted against the reported incidences for common aneuploidies trisomy 21, 45,X, trisomy 18, and trisomy 13.](fgene-10-01162-g005){#f5}

###### 

Known and estimated prevalence of pCNV by linear regression analysis.

  Type of abnormality                                        Reported prevalence\*                  Estimated prevalence
  ---------------------------------------------------------- -------------------------------------- ----------------------
  DiGeorge/velocardiofacial syndrome                         0.0625%--0.05% (1/1,600--1/2,000)      /
  Williams-Beuren syndrome                                   0.013%--0.005% (1/7,500--1/20,000)     /
  Prader-Willi/Angelman syndrome                             0.014%--0.011% (1/7,142--1/9,090)      /
  Smith-Magenis syndrom                                      0.006%%--0.004% (1/15,000--1/25,000)   /
  Hereditary neuropathy with liability to pressure palsies   0.016% (1/6250)                        /
  1q21.1 deletion syndrome                                   /                                      0.009% (1/10,965)
  1q21.1 duplication syndrome                                /                                      0.017% (1/5,960)
  3q29 deletion syndrome                                     /                                      0.010% (1/9,839)
  16p11.2 deletion syndrome                                  /                                      0.020% (1/5,025)
  17q12 deletion syndrome                                    /                                      0.009% (1/10,965)
  **Recurrent genomic disorders**                            **/**                                  **0.250% (1/396)**
  **All pCNVs**                                              **/**                                  **0.344% (1/291)**

\*Reported prevalence from [@B11]; [@B16]; [@B22]; [@B37]; [@B27]; and [@B31].

The correlation between the incidences of selected chromosomal abnormalities in live births with their ADR in pediatric patients was determined (Y = 0.0343X + 0.0045; R² = 0.9987, p = 0.00065) ([**Figure 5B**](#f5){ref-type="fig"} and [**Table 4**](#T4){ref-type="table"}). Using this linear regression correlation, the incidence of other chromosomal abnormalities was estimated as: 0.0254% (1/3933) for 47,XXY, 0.01% (1/10012) for 47,XXX, 0.0083% (1/12088) for 47,XYY, and 0.0076% (1/13180) for balanced Robertsonian translocations. These estimated incidences were much lower than the previously published incidences in live births ([@B25]). This result indicated that current pediatric genetic evaluation was effective in identifying trisomy 21, 45,X, trisomy 18, and trisomy 13, but was not effective in identifying other sex chromosomal aneuploidies and balanced Robertsonian translocations.

###### 

Estimated incidence of chromosomal abnormalities by linear regression analysis.

  Type of abnormality     Incidence in live births\*   Under-estimated incidence
  ----------------------- ---------------------------- ---------------------------
  45,X                    0.025% (1/4,000)             /
  trisomy 21              0.12% (1/830)                /
  trisomy 18              0.0133% (1/7,500)            /
  trisomy 13              0.0044% (1/22,700)           /
  47,XXY                  0.1% (1/1,000)               0.0254% (1/3,933)
  47,XYY                  0.1% (1/1,000)               0.0083% (1/12,088)
  47,XXX                  0.11% (1/900)                0.0100% (1/10,012)
  Balanced Robertsonian   0.09% (1/1,100)              0.0076% (1/13,180)

\*Incidence of chromosome abnormalities by [@B25].

Estimation of Diagnostic Efficacy From Served Population {#s3_4}
--------------------------------------------------------

The Yale Clinical Cytogenetics Laboratory provides diagnostic services to the population in New Haven and its surrounding counties in southern Connecticut. The population in New Haven County is 0.9 million and in Connecticut State is 3.6 million. Based on the 1.0% birth rate in annual registration reports (2009 to 2015) from Connecticut Department of Public Health, there should be about 36,000 newborns in Connecticut per year. With known incidence of Down syndrome (DS) of 1/830 and DGS of 1/4,000, 45 newborns with DS and 9 newborns with DGS are expected in the State of Connecticut each year. This study detected 377 DS cases and 50 DGS cases in a 10-year interval, with an estimated diagnosis of 38 DS cases and 5 DGS cases per year accounting for 55%--85% of the expected cases in Connecticut. Considering there were overlapping DS cases from prenatal testing and follow up pediatric testing, it was estimated that the patients referred for cytogenomic testing were likely from a base of 60% of the Connecticut population, which is about two million residing in New Haven County and the surrounding area. Two million was used as the population size our lab served.

To estimate the diagnostic efficacy, the number of cases of chromosomal abnormalities and pCNVs based on their newborn incidences was compared with diagnostic results based on one million population size ([**Table 5**](#T5){ref-type="table"}). It could be assumed that diagnostic efficacy at 90% or higher is highly effective, 50%--90% is variably effective, and below 50% is under detection. The overall diagnostic efficacy for cytogenomic abnormalities was about 29% in prenatal cases and 35% in pediatric cases. For chromosome abnormalities, the diagnostic efficacy of 92% for prenatal detection of DS and TS (45,X) should be considered highly effective. The efficacy for detecting 47,XXY, 47,XXX, 47,XYY, and Robertsonian translocations ranged from 1%--4% in prenatal practice and 2%--14% in pediatric evaluation indicated under detection. Assumed no overlapping cases between prenatal and pediatric cases, 42% of chromosomal abnormalities and 4% of pCNVs were detected prenatally and an additional 28% chromosomal abnormalities and 48% of pCNVs were detected postnatally.

###### 

Estimated diagnostic efficacy for chromosomal abnormalities and pCNVs.

  Type of cytogenomic abnormality       Incidence in newborns^a^   Expected cases per 10,000 newborns^b^   Prenatal setting   Pediatric setting              
  ------------------------------------- -------------------------- --------------------------------------- ------------------ ------------------- ---------- ---------
  Trisomy 21                            1/830                      12                                      11                 92%                 7.5        63%
  45,X                                  1/4,000                    2.5                                     2.3                92%                 1.2        48%
  47,XXY                                1/1,000                    10                                      0.4                4%                  1.4        14%
  47,XXX                                1/900                      11                                      0.4                4%                  0.4        4%
  47,XYY                                1/1,000                    10                                      0.1                1%                  0.3        3%
  Balanced Rob.                         1/1,100                    9                                       0.3                3%                  0.2        2%
  **All chromosome abnormalities**      **1/154**                  **64**                                  **27**             **42%**             **18**     **28%**
  DGS/VCFS                              1/4,000                    2.5                                     0.2                8%                  2.3        92%
  16p11.2 del                           1/5,800                    1.7                                     0                                      0.75       44%
  1q21.1 del                            1/7,400                    1.4                                     0                                      0.25       18%
  PWS/AS                                1/8,000                    1.25                                    0                                      0.85       68%
  WBS                                   1/10,000                   1                                       0                                      0.4        40%
  **All recurrent genomic disorders**   **1/396**                  **25**                                  **0.85**           **3%**              **11.6**   **46%**
  **All pCNVs**                         **1/291**                  **33**                                  **1.3**            **4%**              **16**     **48%**
  **Total cytogenomic abnormalities**   **1/100**                  **97**                                  **28.3**           **29%**             **34**     **35%**

Rob, Robertsonian translocation; DGS/VCFS, DiGeorge/velocardiofacial syndrome; PWS/AS, Prader-Willi/Angelman syndrome; WBS, Williams-Beuren syndrome; pCNVs, pathogenic copy number variants.

Incidence of cytogenomic abnormalities in newborns by [@B25], [@B43] and this study;

Expected cases derived from incidence and detected cases from average annual abnormal cases based on 1.0% birth rate from Connecticut Department of Public Health and estimated 2 million population served by Yale Clinical Cytogenetics Laboratory. Diagnostic efficacy was estimated by detected cases/expected cases.

The ratio of DS cases vs DGS cases (DS/DGS) from their incidences should be about 4 to 5 (1/830 vs 1/4,000). This DS/DGS ratio could be used as a simple measurement for efficacy in detecting chromosome abnormalities and pCNVs. The DS/DGS ratio from this study was 57 (227/4) in prenatal cases and 3.3 (150/46) in pediatric cases. The extremely high prenatal DS/DGS ratio indicated under detection of DGS in the prenatal testing. The lower pediatric DS/DGS ratio may be affected by decreased cases of DS from effective prenatal testing.

Discussion {#s4}
==========

It has been over 10 years since the integration of microarray analysis into the clinical cytogenetics diagnostic services for prenatal and pediatric cases. The dual processing of DNA-based aCGH and cell-based karyotyping and FISH ensured analytical validity and diagnostic accuracy for detecting cytogenomic abnormalities. The accuracy from aCGH analysis can achieve over 99% sensitivity and specificity ([@B45]). This retrospective analysis was based on consecutive clinical referrals and standardized aCGH, karyotyping, and FISH analyses performed in a laboratory, a similar spectrum of cytogenomic abnormalities was observed but different ADR and RF for types of abnormalities were obvious between prenatal and pediatric cases.

Difference of Diagnostic Yield in the Spectrum of Cytogenomic Abnormalities Between the Prenatal and Pediatric Settings {#s4_1}
-----------------------------------------------------------------------------------------------------------------------

In prenatal cases, chromosomal abnormalities and pCNVs accounted for 95% (534/560) and 5% (26/560) of the total abnormalities, respectively. While in pediatric patients, chromosomal abnormalities and pCNVs accounted for 53% (354/674) and 47% (320/674) of the total abnormalities, respectively. Among cases with chromosomal abnormalities, numerical and structural chromosomal abnormalities accounted for 88% and 12% in prenatal cases, and 64% and 36% of pediatric patients, respectively. Under detection of 47,XXY, 47,XXX, 47,XYY, and balanced Robertsonian translocations was evident from their ADR and RF, as well as under estimated incidences of these abnormalities in the liner regression analysis. The mild phenotypes of these cases during childhood likely explain the under detection. Clinical attention in a different setting or at a different time such as genetic evaluation for reproductive failure or other age-related symptoms may allow detection of some portion of these chromosomal abnormalities later.

The diagnostic efficacy for pCNVs showed a clear under detection in prenatal practice and variable efficiency in pediatric practice. It is estimated that only 8% of DGS was detected in prenatal diagnosis. In pediatric genetic analysis, the diagnostic efficacy of 92% for DGS was highly effective and of 40%--68% for WBS, PWS/AS and 16p11.2 deletion showed variability. For recurrent genomic disorders and all pCNVs, approximately 3% and 4% were detected prenatally and 46% and 48% were detected postnatally, respectively. From the linear regression analysis, the prevalence of other common genomic disorders such as 1q21.1 microdeletion and microduplication syndrome, 16p11.2 microdeletion syndrome, 3q29 deletion syndrome, and 17q12 deletion syndrome was similar to those reported from other studies ([@B36]; [@B10]). The prevalence of all recurrent genomic disorders was estimated to be 1/396 and of all pCNVs was 1/291. Combining the prevalence of 1/291 for pCNVs with 1/154 for chromosomal abnormalities ([@B25]), the prevalence of all cytogenomic abnormalities is about 1/100.

Current phenotype-first analysis could lead to under detection of recurrent genomic disorders and sporadic pCNVs due to variable expressivity and incomplete penetrance causing under estimation of prevalence. A genotype-first epidemiological study in a large population is the best way to determine the prevalence of pCNVs. Although the estimated prevalence for recurrent genomic disorders or pCNVs varied and thus affect the evaluation of diagnostic efficacy, approaches to improve the diagnostic yield of pCNVs should be considered.

Approaches to Improve the Diagnostic Yield of Cytogenomic Abnormalities in Prenatal Clinical Practice {#s4_2}
-----------------------------------------------------------------------------------------------------

Prenatal diagnosis is currently performed on pregnant women at risk for genetic disorders. The clinical indications for cytogenomic analysis include abnormal results by non-invasive prenatal testing (NIPT) of maternal plasma cell-free fetal DNA, abnormal ultrasound findings (aUS), abnormal maternal serum screening (aMSS), advanced maternal age (AMA), family history (FH) of chromosomal abnormalities, parental anxiety, and other adverse fetal health events. Since 2000, the development of sensitive ultrasonic technology and utilization of maternal serum markers have increased aUS and aMSS as indications for prenatal cytogenetic analysis and decreased AMA as an indication ([@B17]; [@B21]). The introduction of NIPT has significantly reduced the invasive AF and CVS procedures and increased the ADR; which explained the continuous decrease of prenatal cases during 2008--2012 in this report. A recent study showed that the NIPT performed significantly better in predicting sex chromosome trisomies than monosomy X; which could potentially improve the under detection of sex chromosome aneuploidy in prenatal diagnosis ([@B48]). The integration of aCGH in prenatal diagnosis has extended its diagnostic scope to include pCNVs ([@B18]; [@B6]). In this study, aCGH was performed in about one third of total prenatal cases with an ADR of 2.59% for pCNVs. Application of aCGH to the other two third of the cases with normal karyotype is expected to detect a similar percentage of pCNVs. A multicenter study by the National Institute of Child Health and Human Development (NICHD) showed that pCNVs were detected in 2.5% of all prenatal cases by microarray analysis ([@B41]). This NICHD multicenter study revealed that in samples with a normal karyotype, pCNVs were detected in 6.0% of fetuses with ultrasound anomalies and in 1.7% of those with AMA, aMSS or parental anxiety. A study on 5,026 consecutive prenatal specimens by high resolution microarray analysis detected pCNV in 3% of cases ([@B40]). A systematic review of 19 studies and meta-analysis of the 10 largest studies in a pooled cohort of 10,614 fetuses showed that 0.84% of fetuses investigated by invasive prenatal testing due to AMA and parental anxiety had a pathogenic clinically signiﬁcant submicroscopic aberrations; of which, pCNVs associated with early-onset syndromic disorders accounted for 0.37% of cases, pCNVs associated with late-onset syndromic disorders accounted for 0.11% of cases, and susceptible CNVs in 0.30% of cases ([@B35]). A cohort study found an excess ADR of 4.1% by microarray analysis over conventional karyotyping when the clinical indication for testing was abnormal fetal ultrasound findings; and this excess detection rate increased to 10% in the author's meta-analysis ([@B13]). In another study of 1,033 fetuses with ultrasound anomalies, pathogenic submicroscopic abnormalities were identified in 5.5% of cases ([@B34]). Lack of easily detectable anatomical abnormality in many of the pCNVs likely contribute to their low detection rate in the prenatal setting. Several studies reported that ultrasonographic fetal anomalies such as heart defects, overgrowth or undergrowth, and limb defects had been used as clinical indications for prenatal testing of DGS, Jacobsen syndrome, Cri du Chat syndromes, split hand/foot malformations and Simpson-Galobi-Bemhel syndrome ([@B8]; [@B49]; [@B21]; [@B9]).

Currently, prenatal chromosomal microarray analysis is recommended for pregnant women with a fetus showing one or more major structural abnormalities identified by ultrasonographic examination ([@B7]). The major challenge for prenatal diagnosis is to improve the screening efficiency and thus increase the diagnostic yield of pCNVs for better management of birth defects, especially for the well-recognized syndromic genomic disorders ([@B20]; [@B40]). However, most prenatal screening programs mainly determine the risk of common aneuploidies and seldom predict the risk of submicroscopic pCNVs ([@B14]; [@B3]; [@B4]). Improved SNP-based NIPT was developed to screen for a subset of submicroscopic abnormalities. A study of 21,948 samples submitted for screening of DGS/VCFS by SNP-based NIPT identified 95 cases as high risk for fetal DGS/VCFS; 61 of those were further analyzed by a diagnostic test and confirmed 11 true positives and 50 false positives, indicating a positive predictive value of 18.0% ([@B12]). The performance of SNP-based NIPT in 80,449 referrals for DGS/VCFS and 42,326 referrals for 1p36, cri-du-chat, Prader-Willi/Angelman microdeletion syndromes and a comparison of original screening protocol with a revision that reflexively sequenced high-risk calls at a higher depth of reads were retrospectively analyzed ([@B20]). The positive predictive value of the original screening was 15.7% for DGS/VCFS and 5.2% for the other four disorders combined. With the revised protocol, these values increased to 44.2% for DGS/VCFS and 31.7% for the others. The risk of pCNVs under different prenatal clinical indications is summarized in [**Table 6**](#T6){ref-type="table"}.

In summary, to improve the yield of pCNVs in prenatal diagnosis, the first approach is to extend aCGH for more prenatal cases; the second approach is to establish reliable correlations between genomic disorders and ultrasonagraphic fetal anomalies and use them as clinical indications in genetic counseling for a complete prenatal cytogenomic testing; and the third approach is to enhance the analytical resolution of NIPT to screen for both chromosomal aneuploidies and common genomic disorders. The enhanced NIPT results could be a more effective predicator for pCNVs and should be considered for the general pregnant population regardless of maternal age and other clinical indications ([@B42]).

###### 

Clinical indications and the risk of pCNVs from prenatal studies.

  Indications                    Risk of pCNVs   References
  ------------------------------ --------------- ----------------------------
  Mix indications                2.5%--3%        [@B41], [@B40], this study
  AMA, aMSS, parental anxiety    0.84%--1.7%     [@B41], [@B35]
  Abnormal ultrasound findings   4.1%--10%       [@B41], [@B13], [@B34]
  NIPT^a^                        5.2%--18%       [@B12], [@B20]
  NIPT enhanced ^b^              31.7%--44.2%    [@B20]

AMA, advanced maternal age; aMSS, abnormal maternal serum screening; NIPT, non-invasive prenatal testing; pCNVs, pathogenic copy number variants;

^a^in screening for 22q11.2 deletion syndrome and 1p36, cri-du-chat, Prader-Willi, and Angelman microdeletion syndromes.

^b^enhanced NIPT by using high depth sequencing.

Cytogenomic Aberrations Not Detectable by Microarray Analysis {#s4_3}
-------------------------------------------------------------

In this study, the ADR for balanced structural chromosomal abnormalities in prenatal and pediatric cases was 0.92% and 0.63%, respectively, which were consistent with the 0.78%--1.3% reported in the ACMG practice resource ([@B39]). These balanced structural chromosomal abnormalities, including reciprocal translocations, insertions, inversions, and balanced Robertsonian translocations, are not detectable by microarray analysis. Professional recommendations stated that ordering providers should be aware of cytogenomic aberrations not detectable by microarray analysis, including those relevant to various microarray platforms (e.g., SNP versus oligonucleotide) ([@B19]). Although most of balanced rearrangements are benign, several studies indicated that balanced structural rearrangements associated with direct functional gene disruption, truncation, or disruption of regulatory domains would contribute to pathogenic phenotype ([@B5]; [@B26]; [@B50]). Therefore, conventional karyotyping remains valuable in the detection of balanced structural chromosomal abnormalities and mosaicism.

Conclusion {#s5}
==========

The diagnostic yield of cytogenomic abnormalities was evaluated in current prenatal and pediatric settings over a period of 10 years. Detailed analysis on the spectrum of cytogenomic abnormalities indicated high efficacy in prenatal detection of DS and TS and postnatal detection of DGS. Under detection of pCNVs in the prenatal setting and of other sex chromosome numerical abnormalities in both prenatal and postnatal settings were noted. Efficacy for detecting other pCNVs in pediatric setting was variable. Expansion of aCGH analysis to more prenatal cases, more reliable correlations between genomic disorders and fetal ultrasonographic anomalies, and enhanced NIPT screening for well-recognized syndromic genomic disorders are approaches that could improve diagnostic yield of cytogenomic abnormalities in prenatal cases. Better understanding of clinical presentations for sex chromosome numerical abnormalities and pCNVs could help to improve diagnostic yield for pediatric cases. The prevalence of cytogenomic abnormalities in about 1% of newborns may call for the change from phenotype-first detection to genotype-first *surveillance* in clinical practice and potentially contribute to a better clinical management of cytogenomic abnormalities in the future.
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